Evidence map›Paper›PMID 36387436›Full record

ArticleHeliyon2022

Lorena Cayetano-Salazar, Brenda de la Cruz-Concepción, Napoleón Navarro-Tito, Patricia Álvarez-Fitz, Marco A Leyva-Vázquez, Macdiel Acevedo-Quiroz, Ana E Zacapala-Gómez, Carlos Ortuño-Pineda, Dinorah N Martinez-Carrillo, Eduardo Castañeda-Saucedo and 2 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Iranian journal of pharmaceutical research : IJPR
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Lorena Cayetano-SalazarFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Brenda de la Cruz-ConcepciónFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Napoleón Navarro-TitoFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Patricia Álvarez-FitzCONACYT-Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Marco A Leyva-VázquezFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Macdiel Acevedo-QuirozTecnológico Nacional de México, Instituto Tecnológico/IT de Zacatepec, Calzada Tecnológico 27, Centro, Zacatepec 62780, Morelos, Mexico.
Ana E Zacapala-GómezFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Carlos Ortuño-PinedaFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Dinorah N Martinez-CarrilloFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Eduardo Castañeda-SaucedoFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Alejandra P García-HernándezLaboratorio Estatal de Salud Pública, Secretaría de Salud Guerrero, Acapulco 37915, Guerrero, Mexico.
Miguel A Mendoza-CatalánFacultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Ciudad Universitaria, Chilpancingo 39090, Guerrero, Mexico.
Universidad Autónoma de Guerrero · MXSecretaria de Salud · MXTecnológico Nacional de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype due to its greater invasive capacity and non-response to hormone therapy. Several species of the Materials and methods: The phytochemical profile was carried out by gas chromatography-mass spectrometry (GC-MS). Cell proliferation, migration, and invasion were determined by MTT, wound closure, and transwell assays, respectively. MMPs activity was analyzed using gelatin zymography, and fluorescence microscopy was used to visualize F-actin distribution. Results: Hex-EFc, Dic-EFc, and Ace-EFc showed cytotoxic activity on MDA-MB-231 tumor cells and, to a lesser extent, on MCF-7 cells, without presenting cytotoxicity at the same concentrations in MCF-10A non-tumor cells. Dic-EFc and Ace-EFc (5-10 μg/mL) reduced the migration capacity of MCF-7 and MDA-MB-231 cells. Interestingly, exposure to Dic-EFc and Ace-EFc (5-10 μg/mL) inhibited the invasive ability of MDA-MB-231 cells, reducing the secretion and activity of MMP-2 and MMP-9, as well as the F-actin distribution. Conclusions: Dic-EFc and Ace-EFc at low concentrations decreased breast cancer cell proliferation and invasiveness, mainly of MDA-MB-231 cells. The above supports the potential use of compounds from leaf extracts of

Indexed as

Cell invasionComplementary therapyFicusMoraceaeTriple-negative breast cancer

Identifiers

PMID36387436
PMCPMC9647462
OpenAlexW4308545597

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.